Neptune, Aker BioMarine Bury Patent Hatchet
This article was originally published in The Rose Sheet
Executive Summary
The firms say their patent cross-licensing agreement ends all outstanding litigation. Aker gets access to Neptune's composition patents for $10m over a period of 15 months, and Neptune has rights to Aker's select krill oil-related patent portfolio for $4m.
You may also be interested in...
Dr. Teal’s Tucks In Some Melatonin Topical Sleep Claims After P&G Challenge, Keeps Others Awake
PDC Brands declines to provide support for nine challenged claims for Dr. Teal’s line of balms, lotions, oils, soaps, sprays and other topicals. It continues using those after halting use of 25 other similar claims challenged by P&G, marketer of melatonin-containing ZzzQuil.
NPA Complaint For Preemption Argues New York Swings Wildly With Age-Restricted Sales Law
New York law crosses so many federal regulations it would also affect Rx drug sales while allowing consumers to file complaints alleging businesses violate the law, NPA argues in complaint filed in federal court in New York City.
Will Constitution Stop New York's Diet Pill Sales Rule Despite State Age-Restricting DXM OTCs?
NPA argues in complaint that limiting purchases of weight loss and bodybuilding OTC drugs and supplements to consumers 18 and older preempted not only by FD&C Act regulations but also by Commerce Clause of the US Constitution.